Pathogenetic Aspects of the Choice of Drug Therapy in the Treatment of Acute Pancreatitis

Cover Page

Cite item

Full Text

Abstract

Difficulties in determining effective treatment tactics for acute pancreatitis are associated with a complex multifactorial pathophysiological mechanism of the disease development. The central part in the pathogenesis of acute pancreatitis is taken by disorders of pancreatic microcirculation. Regardless of the etiology, increasing changes in microcirculation enhance the degree of pancreatic ischemia, thus intensifying the systemic inflammatory response syndrome and resulting in multisystem organ failure. Initial treatment of patients with moderate-to-severe and severe acute pancreatitis combined with transient or persistent organ failure should be carried out in intensive care units. Currently, there are no drugs effective for the treatment of acute pancreatitis in clinical practice. Initial treatment of various forms of acute pancreatitis is essentially supportive and aimed at relieving pain, nausea and vomiting, infusion therapy and early enteral nutrition. Indications for the use of antibacterial therapy in necrotizing acute pancreatitis are cases of infected pancreatic necrosis confirmed by CT or fine-needle aspiration biopsy, or clinical suspicion of infecting necrotic accumulations. To assess the severity and treat patients with severe acute pancreatitis, coordinated work of a multidisciplinary team of specialists is necessary. In the early stage of severe acute pancreatitis, responsibility for coordinating such multidisciplinary work should be borne by specialists of the intensive care units, at a late stage (in 2 weeks), such a role should be played by surgeons, determining the tactics of treating complications of necrotizing forms of acute pancreatitis and the use of various options for invasive interventions.

About the authors

Vladimir N. Ektov

N.N. Burdenko Voronezh State Medical University

Author for correspondence.
Email: ektov.vladimir@yandex.ru
ORCID iD: 0000-0001-9422-1776
SPIN-code: 4834-4717
Scopus Author ID: 6603195283

M.D., Professor of the Department of Specialized Surgical Disciplines, N.N. Burdenko

Russian Federation, Voronezh

Mark A. Khodorkovsky

N.N. Burdenko Voronezh State Medical University

Email: vgmi_30@mail.ru
ORCID iD: 0000-0003-2584-0471
SPIN-code: 3357-4960
Scopus Author ID: 58025021800

M.D., Professor of the Department of Specialized Surgical Disciplines, N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh

Alexander V. Kurkin

N.N. Burdenko Voronezh State Medical University

Email: av_kurkin@mail.ru
ORCID iD: 0009-0008-5217-2097
SPIN-code: 2241-6585

Ph.D., Assistant of the Department of Specialized Surgical Disciplines

Russian Federation, Voronezh

References

  1. Sah RP, Garg P, Saluja AK. Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol. 2012;28(5):507–15. doi: 10.1097/MOG.0b013e3283567f52
  2. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. 1998;175(1):76–83. doi: 10.1016/s0002-9610(97)00240-7.
  3. Firsova VG, Parshikov VV, Gradusov VP. Tactical Issues of Treatment of Fluid Collections According to the Revised Atlanta Classifiction of Local Complications of Acute Pancreatitis. Journal of Experimental and Clinical Surgery. 2016;9(2):114-123. (in Russ.)
  4. Fischer SK, Williams K, Wang L, Capio E, Briman M. Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis. Bioanalysis. 2019; 11:1777–85. doi: 10.4155/bio-2019-0192
  5. Inoue K, Hirota M, Kimura Y, Kuwata K, Ohmuraya M,Ogawa M. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. Pancreas. 2003; 26(3):218–23. doi: 10.1097/00006676-200304000-00002.
  6. Plusczyk T, Rathgeb D, Westermann S, Feifel G. Effects of somatostatin (SMS) on pancreatic microcirculation. Dig Dis Sci. 1997;42:2254–63. doi: 10.1023/a:1018862616845. – EDN AKFZTF.
  7. Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg. 2006; 93:518–30. doi: 10.1002/bjs.5316
  8. Knoefel WT, Kollias N, Warshaw A, Waldner H, Nishioka NS, Rattner DW. Pancreatic microcirculatory changes in experimental pancreatitis of graded severity in rat. Surgery. 1994;116: 904–13. PMID: 7940196
  9. Strate T, Mann O, Kleinhans H, Rusani S, Schneider C, Yekebas E. Microcirculatory function and tissue damage is improved after therapeutic injection of bovine hemoglobin in severe acute rodent pancreatitis. Pancreas. 2005;30:254–9. doi: 10.1097/01.mpa.0000157481.22155.2d.
  10. Yin J, Chen Z, Niu W, Feng L, Fan B, Zhou L, Zeng B, Zhang J, Chen H, Tong B, Tong L, Chen X. Using a multidisciplinary team for the staged management and optimally minimally invasive treatment of severe acute pancreatitis. Biosci Trends. 2021;15(3):180–187. doi: 10.5582/bst.2021.01075. – EDN XDYLTM.
  11. Easler JJ, Mounzer R, Papachristou GI. Pharmacological therapy for acute pancreatitis: where are we now? Where are we going? Minerva Gastroenterol Dietol. 2012;58:365–76. PMID: 23207613
  12. Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154–68. doi: 10.1097/01.sla.0000197334.58374.70. – EDN YWCYJB.
  13. Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicenter trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97–104. doi: 10.1136/gut.45.1.97.
  14. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28:369–73. doi: 10.1097/00006676-200405000-00003.
  15. Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010;39:863–7. doi: 10.1097/MPA.0b013e3181d37239. doi: 10.1097/MPA.0b013e3181d37239.
  16. Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol. 2008;14:6382–7. doi: 10.3748/wjg.14.6382.
  17. Zhou M, Chen B, Sun H, Chen X, Yu Z, Shi H. The efficiency of continuous regional intra-arterial infusion in the treatment of infected pancreatic necrosis. Pancreatology. 2013; 13:212–5. doi: 10.1016/j.pan.2013.02.004. – EDN FYFONZ.
  18. Hamada T, Yasunaga H, Nakai Y, Isayama H, Horiguchi H, Matsuda S. Continuous regional arterial infusion for acute pancreatitis: a propensity score analysis using a nationwide administrative database. Crit Care. 2013;17:R214. doi: 10.1186/cc13029. – EDN HXGRWX.
  19. Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut. 2007;56:1439–44. doi: 10.1136/gut.2006.115873.
  20. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, MoslerP, Higgins PD. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012; 366:1414–22. doi: 10.1056/NEJMoa1111103.
  21. Tenner S, Baillie J, DeWitt J, Vege SS, American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9): 1400–15. doi: 10.1038/ajg.2013.218. – EDN RKXRXJ.
  22. Helm JF, Venu RP, Geenen JE, Hogan WJ, Dodds WJ, ToouliJ. Effects of morphine on the human sphincter of Oddi. Gut. 1988;29 (10):1402–7. doi: 10.1136/gut.29.10.1402
  23. Thune A, Baker RA, Saccone GT, Owen H, Toouli J. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg. 1990;77(9):992–5. doi: 10.1002/bjs.1800770911.
  24. Stigliano S, Sternby H, de Madaria E, Capurso G, Petrov MS. Early management of acute pancreatitis: a review of the best evidence. Dig Liver Dis. 2017; 49: 585–594. doi: 10.1016/j.dld.2017.01.168. – EDN YGGMVO.
  25. Leppäniemi A, Tolonen M, Tarasconi А.2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27. doi: 10.1186/s1301701902470– EDN MSWSPE.
  26. Working Group IAP/APA. Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1–15. doi: 10.1016/j.pan.2013.07.063. – EDN UTWLVL.
  27. Yokoe M, Takada T, Mayumi T. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci. 2015; 22:405–432. doi: 10.1002/jhbp.259. – EDN UPXOON.
  28. Baillargeon JD, Orav J, Ramagopal V, Tenner SM, Banks PA. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol.1998;93:2130–4. doi: 10.1111/j.1572-0241.1998.00608.x.
  29. Wu BU , Hwang JQ , Gardner TH. Lactated Ringer’s solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011; 9: 710–7. doi: 10.1016/j.cgh.2011.04.026.
  30. Arvanitakis М, Dumonceau JM, Albert J. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy. 2018; 50: 524–546. doi: 10.1055/a05885365 – EDN WWDCYJ.
  31. Wang MD, Ji Y, Xu J, Jiang DH, Luo L, Huang SW. Early goal-directed fluid therapy with fresh frozen plasma reduces severe acute pancreatitis mortality in the intensive care unit. Chin Med J (Engl). 2013;126(10):1987–8. PMID: 23673124
  32. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
  33. Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. N Engl J Med 2016; 375: 1972–1981. doi: 10.1056/NEJMra1505202.
  34. Lee PJ, Papachristou GI. Management of Severe Acute Pancreatitis. Curr Treat Options Gastroenterol. 2020 doi: 10.1007/s1193802000322x
  35. Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, Rydzewska G. Fluid resuscitation in acute pancreatitis: normal saline or lactated Ringer’s solution? World J Gastroenterol. 2015;21:9367–72. doi: 10.3748/wjg.v21.i31.9367
  36. Iqbal U, Anwar H, Scribani M. Ringer’s lactate versus normal saline in acute pancreatitis: a systematic review and meta-analysis. J Digest Dis. 2018;19:335–41. doi: 10.1111/1751-2980.12606.
  37. Eckerwall G , Olin H , Andersson B. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: what have we learned and how can we do better? Clin Nutr. 2006 ; 25 : 497 – 504. doi: 10.1016/j.clnu.2005.10.012.
  38. De Madaria E, Soler-Sala G, Sánchez-Payá J. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. Am J Gastroenterol. 2011; 106: 1843 –1850. doi: 10.1038/ajg.2011.236. – EDN PHTCRT.
  39. Kuwabara K, Matsuda S, Fushimi K. Early crystalloid fluid volume management in acute pancreatitis: Association with mortality and organ failure. Pancreatology. 2011; 11: 351 – 361. doi: 10.1159/000328965.
  40. Gad М, Simons-Linares С. Is aggressive intravenous fluid resuscitation beneficial in acute pancreatitis? A meta-analysis of randomized control trials and cohort studies. World J Gastroenterol. 2020; 26(10): 1098-1106. doi: 10.3748/wjg.v26.i10.1098.
  41. Li L, Jin T, Wen S, Shi N, Zhang R, Zhu P, Lin Z, Jiang K, Guo J, Liu T, Philips A, Deng L, Yang X, Singh VK, Sutton R, Windsor JA, Huang W, Xia Q. Early rapid fluid therapy is associated with increased rate of noninvasive positive-pressure ventilation in hemoconcentrated patients with severe acute pancreatitis. Dig Dis Sci. 2020;65(9):2700–11. doi: 10.1007/s10620-019-05985-w. – EDN SNOYSE.
  42. De Laet IE, Malbrain MLNG, De Waele JJ. A clinician’s guide to management of intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients. Crit Care. 2020;24:97.–46. doi: 10.1186/s13054-020-2782-1.
  43. Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D, Funk D, Turgeon AF, Abou-Setta AM, Zarychanski R. Incorporating dynamic assessment of fluid responsiveness in to goal-directed therapy: a systematic review and meta-analysis. Crit Care Med. 2017;45:1538–45. doi: 10.1097/CCM.0000000000002554.
  44. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Guidelines for intensive care unit admission, discharge, and triage. Crit Care Med. 1999;27:633-8. PMID: 10199547
  45. Company L, Saez J, Martinez J, Aparicio J R, Laveda R, Grino P. Factors predicting mortality in severe acute pancreatitis. Pancreatology. 2003;3(2):144–148. doi: 10.1159/000070083.
  46. Pupelis G, Plaudis H, Zeiza K, Drozdova N, Mukans M, Kazaka I. Early continuous veno-venous haemofiltration in the management of severe acute pancreatitis complicated with intra-abdominal hypertension: retrospective review of 10 years’ experience. Ann Intensive Care. 2012;2:S21. doi: 10.1186/2110-5820-2-S1-S21
  47. Xu J, Tian X, Zhang C, Wang M, Li Y. Management of abdominal compartment syndrome in severe acute pancreatitis patients with early continuous veno-venous hemofiltration. Hepatogastroenterology. 2013; 60:1749–52. doi: 10.5754/hge13351.
  48. Rendon JL, Choudhry MA. Th17 cells: critical mediators of host responses to burn injury and sepsis. J Leukoc Biol. 2012;92:529–38. doi: 10.1189/jlb.0212083.
  49. Guo J, Li Z, Tang D, Zhang J. Th17/Treg imbalance in patients with severe acute pancreatitis: attenuated by high-volume hemofiltration treatment. Medicine. 2020;99:31(e21491) doi: 10.1097/MD.0000000000021491
  50. Guo Y, Cao F, Li C, Yang H, Xia S, Li F. Сontinuous hemofiltration reduces mortality in severe acute pancreatitis: a meta-analysis. Emerg Med Int. 2020, Article ID 6474308, 10 p. doi: 10.1155/2020/6474308
  51. Lin Y, He S, Gong J, Ding X, Liu Z, Gong J, Zeng Z, Cheng Y. Continuous veno-venous hemofiltration for severe acute pancreatitis. Cochrane Database Syst Rev. 2019;10(10):CD012959. doi: 10.1002/14651858.CD012959.pub2
  52. Teerenhovi O, Nordback I, Eskola J. High volume lesser sac lavage in acute necrotizing pancreatitis. Br J Surg. 1989;76:370-3. doi: 10.1002/bjs. 1800760418
  53. Ihse I, Evander A, Gustafson I, Holmberg J T. Influence of peritoneal lavage on objective prognostic signs in acute pancreatitis. Ann Surg. 1986; 204:122-7. doi: 10.1097/0000065819860800000004
  54. Ranson JH, Berman RS. Long peritoneal lavage decreases pancreatic sepsis in acute pancreatitis. Ann Surg. 1990; 211:708-16, discussion 716-8. doi: 10.1097/0000065819900600000009
  55. Dong Z, Petrov M S, Xu J, Shanbhag S, Windsor JA, Pang S. Peritoneal lavage for severe acute pancreatitis: a systematic review of randomised trials. World J Surg. 2010; 34:2103-8. doi: 10.1007/s0026801006653 – EDN NIPWWA.
  56. Koh Y. Update in acute respiratory distress syndrome. J Intensive Care. 2014;2(1):2. doi: 10.1186/2052-0492-2-2. – EDN VZBYAP.
  57. Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. World J Gastroenterol. 2012;18:279–84. doi: 10.3748/wjg.v18.i3.279.
  58. Lim CL, Lee W, Liew YX, Tang SS, Chlebicki MP, Kwa AL. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis. J Gastrointest Surg. 2015;19:480–91. doi: 10.1007/s11605-014-2662-6. – EDN MAWHEN.
  59. Baron T, DiMaio C, Wang A, Morgan K. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2020;158:67–75. doi: 10.1053/j.gastro.2019.07.064. – EDN NJQJRI.
  60. Trikudanathan G, Navaneethan U, Vege SS. Intra-abdominal fungal infections complicating acute pancreatitis: a review. Am J Gastroenterol. 2011;106:1188–92. doi: 10.1038/ajg.2010.497. – EDN PAHZPR.
  61. Mourad MM, Evans R, Kalidindi V, Navaratnam R, Dvorkin L, Bramhall SR. Prophylactic antibiotics in acute pancreatitis: endless debate. Ann R Coll Surg Engl. 2017; 99:107–12. doi: 10.1308/rcsann.2016.0355. – EDN ZTIEMY.
  62. Reuken PA, Albig H, Rödel J, Hocke M, Will U, Stallmach A, et al. Fungal infections in patients with infected pancreatic necrosis and pseudocysts: risk factors and outcome. Pancreas. 2018;47:92–8. doi: 10.1097/MPA.0000000000000965.
  63. Runzi M, Niebel W, Goebell H, Gerken G, Layer P. Severe acute pancreatitis: nonsurgical treatment of infected necrosis. Pancreas. 2005;30:195–9. doi: 10.1097/01.mpa.0000153613.17643.b3.
  64. Garg PK, Sharma M, Madan K, Sahni P, Banerjee D, Goyal R. Primary conservative treatment results in mortality comparable to surgery in patients with infected pancreatic necrosis. Clin Gastroenterol Hepatol. 2010;8:1089–94. doi: 10.1016/j.cgh.2010.04.011. – EDN HEVBJN.
  65. Mouli VP, Vishnubhatla S, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: a systematic review and meta-analysis. Gastroenterology. 2013;144:333–40. doi: 10.1053/j.gastro.2012.10.004. – EDN YWXUAA.
  66. Otto W, Komorzycki K, Krawczyk M. Efficacy of antibiotic penetration into pancreatic necrosis. HPB. 2006;8(1):43-8. doi: 10.1080/13651820500467275.
  67. Wacke R, Forster S, Adam U. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother. 2006;58:994–9. doi: 10.1093/jac/dkl353.
  68. Schubert S, Dalhoff A. Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas. Antimicrob Agents Chemother. 2012;56(12):6434-6. doi: 10.1128/AAC.00872-12.
  69. Li XY, He C, Zhu Y, Lu NH. Role of gut microbiota on intestinal barrier function in acute pancreatitis. World J Gastroenterol. 2020;26(18):2187-2193. doi: 10.3748/wjg.v26.i18.2187.prof. B.M. Kostyuchenka. 2019; 6: 2:40 - 43. doi: 10.25199/2408-9613-2019-6-2-40-43 (in Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».